RESUMEN
The article lists, characterizes, and discusses the mechanism of the action of endosorbents possessing hypocholesteremic and hypolipidemic effects. Among them are natural endosorbents--food fibers (cellulose, hemicellulose, pectins, gum, mucus, lignin and chitin compounds, etc.); artificial specific affinin and nonspecific carbonic enterosorbents (carbonitrate family, granulated, fibrous), as well as silica (aerosil, polysorb). The effectiveness and pathogenetic expediency of correcting disorders of lipid metabolism in atherosclerosis with enterosorbents is substantiated.
Asunto(s)
Arteriosclerosis/terapia , Enteroadsorción , Animales , Carbón Orgánico/uso terapéutico , Fibras de la Dieta/uso terapéutico , Enteroadsorción/métodos , Humanos , Pectinas/uso terapéutico , Polisacáridos Bacterianos/uso terapéutico , Dióxido de Silicio/uso terapéuticoRESUMEN
The origin and development of ischemic heart disease (IHD) is attended with activation of lipid free-radical oxidation facilitating further advancement of the disease and with decrease of the organism's antioxidant protection. The antianginal drugs which are used in IHD treatment differ in their effect on the blood lipid composition and their peroxidation. beta-Adrenoblocking agents may cause proatherogenic disorders of the blood lipid graph, this increases the risk of IHD advancement. Long-acting nitro preparations are lipid-neutral. Calcium antagonists, mainly those of the nifedipin group, suppress LPO superactivity, possess a high antioxidant effect, and, probably, retard the advancement of coronary atherosclerosis and IHD.
Asunto(s)
Fármacos Cardiovasculares/uso terapéutico , Peroxidación de Lípido/efectos de los fármacos , Lípidos/sangre , Isquemia Miocárdica/sangre , Isquemia Miocárdica/tratamiento farmacológico , Animales , Radicales Libres/sangre , HumanosRESUMEN
The main trends of contemporary pharmacology of hypolipidemic and hypocholesterolemic agents were analysed. A list of drugs capable of correcting lipid metabolism disorders is given: cholesterol absorption inhibitors, stimulators of bile acid synthesis, inhibitors of cholesterol synthesis, analogs of fibroic acid and other inhibitors and correctors of hypertriglyceridemias, stimulators of reverse cholesterol transport and synthesis of high-density lipoproteins, etc. The latest theoretical and experimental elaborations of gene therapy of dyslipoproteinemias in atherosclerosis are discussed.